POM-V Prescription Required Companion Animal

Metrobactin 250 mg Tablets for Dogs and Cats

Active ingredient: Metronidazole

Form

Tablet

Species

Cats Dogs

Manufacturer

Dechra Regulatory B.V.

VMD MA No.

50406/4016

What it's used for

spp. (i.e. C. perfringens C. difficile). Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by obligate anaerobic bacteri...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Metronidazole

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Metrobactin 250 mg Tablets for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

spp. (i.e. C. perfringens C. difficile).
Treatment of infections of the urogenital tract, oral cavity, throat and skin caused by
obligate anaerobic bacteria (e.g. Clostridium spp.).

The recommended dose is 50 mg metronidazole per kg bodyweight per day, for
5-7 days. The daily dose may be divided equally for twice daily administration
(i.e. 25 mg/kg bodyweight twice daily).
To ensure administration of the correct dosage bodyweight should be determined as
accurately as possible.
AN: 00103/2024 & 00104/2024
Tablets can be divided into 2 or 4 equal parts to ensure accurate dosing. Place the
tablet on a flat surface, with its scored side facing up and the convex (rounded) side
facing the surface.
Halves: press down with your thumbs on both sides of the tablet.
Quarters: press down with your thumb in the middle of the tablet.

Do not use in cases of hepatic disorders.
AN: 00103/2024 & 00104/2024
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Dogs, cats:
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Neurological signs
Vomiting
Hepatic toxicosis
Neutropenia
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
Due to the likely variability (time, geographical) in the occurrence of metronidazole
resistant bacteria, bacteriological sampling and susceptibility testing are
recommended.
Whenever possible, the veterinary medicinal product should only be used based on
susceptibility testing.
Official, national and regional antimicrobial policies should be taken into account
when the veterinary medicinal product is used. The tablets are flavoured. In order to
avoid any accidental ingestion, store tablets out of reach of the animals. Especially
after prolonged treatment with metronidazole, neurological signs could occur.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Metronidazole may cause hypersensitivity reactions. People with known
hypersensitivity to metronidazole should avoid contact with the veterinary medicinal
product.
Metronidazole has confirmed mutagenic and genotoxic properties in laboratory
animals as well as in humans. Metronidazole is a confirmed carcinogen in laboratory
animals and has possible carcinogenic effects in humans. However, there is
inadequate evidence in humans for the carcinogenicity of metronidazole.
Metronidazole may be harmful for the unborn child.
Avoid accidental ingestion and contact with the skin or mucous membranes including
hand-to-mouth contact.
To avoid such contact wear impervious gloves when handling the veterinary
medicinal product and/or for direct administration into the animal's mouth.
Do not allow treated dogs to lick persons immediately after intake of the medication.
In case of skin contact, wash thoroughly the affected area.
To avoid accidental ingestion, particularly by a child, unused parts of the tablets
should be returned to the open blister space, inserted back into the outer packaging
and kept in a safe place out of the sight and reach of children. The remaining part
should be used at the time of next administration.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician. Wash hands thoroughly after use.
Special precautions for the protection of the environment:
Not applicable.
AN: 00103/2024 & 00104/2024

Metronidazole may have an inhibitory effect on the degradation of other drugs in the
liver, such as phenytoin, cyclosporine and warfarin.
Cimetidine may decrease the hepatic metabolism of metronidazole resulting in
increased serum concentration of metronidazole.
Phenobarbital may increase hepatic metabolism of metronidazole resulting in
decreased serum concentration of metronidazole.

This veterinary medicinal product does not require any special storage conditions.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.